$0.10
+0.01 (+13.70%)
QNCX News2 articles
Quince Therapeutics Surges on Strategic Review Announcement
Quince Therapeutics shares soared nearly 50% in premarket trading after the company hired LifeSci Capital to explore strategic alternatives and restructure liabilities, following a failed Phase 3 trial.
Quince Therapeutics Engages LifeSci for Strategic Review Amid Phase 3 Setback
Quince Therapeutics shares fell 6.6% in premarket trading after hiring LifeSci Capital to explore strategic alternatives and debt restructuring, following a failed Phase 3 trial and board resignations.